The findings, published Wednesday in the journal Clinical Cancer Research, target triple-negative breast cancer.
,
Breast cancer accounts for up to 15 percent of all diagnosed breast cancers, has a low survival rate and is more common in women under the age of 40.
To investigate the properties of breast cancer cells associated with triple-negative breast cancer, a team from King's College London conducted data analysis using more than 6,000 breast cancer samples.
After understanding how cancer cells escape cancer drugs, the presence of the cancer cell surface marker EGFR as well as the oncogenic molecules cyclin-dependent kinases (CDKs), which are responsible for cell division and proliferation, was established.
Additionally, they also added cetuximab
-Selective antibodies targeting the EGFR protein expressed in this type of cancer form an analogous drug for breast cancer in combination with a CDK-inhibiting drug.
"We were looking for the vulnerabilities of cancer and now we know how we can guide our therapy toward one of these. We used these two properties to create tailored antibody-drug conjugates for patients with this aggressive cancer. Properties used. Mixed medicines." The lead author is Professor Sophia Karagiannis from King's College London.
The researchers noted that since their "antibody-drug conjugate" targets the XX cancer cell, it may be possible to give a lower inhibitory dose than usual and would also be less toxic to the patient. However, he called for more studies before developing the drug.
,
Breast cancer accounts for up to 15 percent of all diagnosed breast cancers, has a low survival rate and is more common in women under the age of 40.
To investigate the properties of breast cancer cells associated with triple-negative breast cancer, a team from King's College London conducted data analysis using more than 6,000 breast cancer samples.
After understanding how cancer cells escape cancer drugs, the presence of the cancer cell surface marker EGFR as well as the oncogenic molecules cyclin-dependent kinases (CDKs), which are responsible for cell division and proliferation, was established.
Additionally, they also added cetuximab
-Selective antibodies targeting the EGFR protein expressed in this type of cancer form an analogous drug for breast cancer in combination with a CDK-inhibiting drug.
"We were looking for the vulnerabilities of cancer and now we know how we can guide our therapy toward one of these. We used these two properties to create tailored antibody-drug conjugates for patients with this aggressive cancer. Properties used. Mixed medicines." The lead author is Professor Sophia Karagiannis from King's College London.
The researchers noted that since their "antibody-drug conjugate" targets the XX cancer cell, it may be possible to give a lower inhibitory dose than usual and would also be less toxic to the patient. However, he called for more studies before developing the drug.
